CompletedPhase 2NCT00006039
Interferon Alfa-2b in Treating Patients With Advanced Low-Grade Non-Hodgkin's Lymphoma
Studying Alpha-heavy chain disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Principal Investigator
- Carol S. Portlock, MDMemorial Sloan Kettering Cancer Center
- Intervention
- pegylated interferon alfa(biological)
- Eligibility
- 18 years · All sexes
- Timeline
- 1999 – 2001
Study locations (1)
- Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00006039 on ClinicalTrials.gov